Cocrystal Pharma Inc (COCP)

Currency in USD
1.6500
+0.0500(+3.13%)
Closed·
1.5800-0.0700(-4.24%)
·
COCP Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
COCP is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.59001.6700
52 wk Range
1.12003.2600
Key Statistics
Prev. Close
1.65
Open
1.59
Day's Range
1.59-1.67
52 wk Range
1.12-3.26
Volume
18.51K
Average Volume (3m)
70.79K
1-Year Change
-6.25%
Book Value / Share
0.72
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
COCP Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
8.0000
Upside
+384.85%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Cocrystal Pharma Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral

Cocrystal Pharma Inc Company Profile

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, a HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was founded in 2006 and is based in Bothell, Washington.

Compare COCP to Peers and Sector

Metrics to compare
COCP
Peers
Sector
Relationship
P/E Ratio
−1.1x−0.5x−0.5x
PEG Ratio
−0.190.090.00
Price/Book
2.3x2.2x2.6x
Price / LTM Sales
-1.5x3.3x
Upside (Analyst Target)
-204.7%41.6%
Fair Value Upside
Unlock12.1%5.9%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 8.0000
(+384.85% Upside)

Earnings

Latest Release
May 15, 2025
EPS / Forecast
-0.23 / -0.49
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

COCP Income Statement

People Also Watch

2.42
INMB
+0.83%
1.660
VOR
-16.58%
0.920
GAME
-5.64%
5.7950
BGLC
+6.53%
2.5600
SNGX
+4.92%

FAQ

What Stock Exchange Does Cocrystal Pharma Trade On?

Cocrystal Pharma is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Cocrystal Pharma?

The stock symbol for Cocrystal Pharma is "COCP."

What Is the Cocrystal Pharma Market Cap?

As of today, Cocrystal Pharma market cap is 16.79M.

What Is Cocrystal Pharma's Earnings Per Share (TTM)?

The Cocrystal Pharma EPS (TTM) is -1.56.

From a Technical Analysis Perspective, Is COCP a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Cocrystal Pharma Stock Split?

Cocrystal Pharma has split 3 times.

How Many Employees Does Cocrystal Pharma Have?

Cocrystal Pharma has 11 employees.

What is the current trading status of Cocrystal Pharma (COCP)?

As of 13 Aug 2025, Cocrystal Pharma (COCP) is trading at a price of 1.65, with a previous close of 1.65. The stock has fluctuated within a day range of 1.59 to 1.67, while its 52-week range spans from 1.12 to 3.26.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.